Simona Nathan
Another significant global public health issue is chronic heart failure (CHF), which affects a large portion of the global population frequently, frequently progresses to a life-threatening condition, and has a high mortality rate. We are interested in learning about recent advancements in the treatment of CHF patients whose left ventricular ejection fraction (LVEF) is less than 40%. In recent years, BNP has been linked to the etiology of cardiac disease. As a result, we set out to investigate the effects of a complex medical treatment plan that combined sacubitril and aspirin, an angiotensin receptor neprilysin inhibitor, on CHF patients. In addition, we investigated the therapeutic strategies used to treat these patients with the device, particularly cardiac resynchronization therapy. Last but not least, we compared the results of cardiac resynchronization therapy to those of a sophisticated medical treatment plan that combined angiotensin receptor neprilysin inhibitor sacubitril and valsartan.
分享此文章
English 
Spanish 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 